Title: C-MET in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Abstract:In recent years epidermal growth factor receptor (EGFR) inhibitor is atreatment a major treatment of non-small cell lung cancer (NSCLC).But with the widespread clinical application of resistance as a ...In recent years epidermal growth factor receptor (EGFR) inhibitor is atreatment a major treatment of non-small cell lung cancer (NSCLC).But with the widespread clinical application of resistance as a new difficulty.Now researchers have discovered the main resistance mechanisms is C-MET oncogene amplification.C-MET is a proto oncogene,a protein product of hepatocyte growth factor/scatter factor (HGF/SF) receptor with tyrosine activity.The amplification of C-MET can activated Erb3-PI3K signaling pathway which result in NSCLC resistant to the EGFR-TKI.The patients who resist to EGFR-TKI for about 20% were due to the amplification of C MET gene.
Key words:
C-MET; Tyrosine Kinase Inhibitors; Non-small cell lung cancer; Epidermal growth factor receptor ; Resistance ; Hepatocyte growth factorRead More
Publication Year: 2012
Publication Date: 2012-10-05
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot